{"analyses":[{"ciLowerLimit":"2.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.95","groupIds":["OG000","OG002"],"nonInferiorityComment":"Treatment A over Treatment C","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"3.52","statisticalMethod":"Stratified Cochran-Mantel-Haenszel"},{"ciLowerLimit":"21.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"35.6","estimateComment":"Strata adjusted difference in objective response rate (Nivolumab+Cabozantinib - Sunitinib) based on DerSimonian and Laird.","groupIds":["OG000","OG002"],"nonInferiorityComment":"Treatment A - Treatment C","nonInferiorityType":"OTHER","paramType":"Difference of Objective Response Rates","paramValue":"28.6"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.1","upperLimit":"61.2","value":"55.7"},{"groupId":"OG001","lowerLimit":"30.0","upperLimit":"58.7","value":"44.0"},{"groupId":"OG002","lowerLimit":"22.4","upperLimit":"32.3","value":"27.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"328"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants.\n\nComplete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG000","title":"Treatment A"},{"description":"Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses)\n\nThen\n\nNivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG001","title":"Treatment B"},{"description":"Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle","id":"OG002","title":"Treatment C"}],"paramType":"NUMBER","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"Up to 31 Months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}